Clinical Trials Logo

Clinical Trial Summary

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine, in terms of progression-free survival (PFS), the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organization (WHO) grade II meningioma. SECONDARY OBJECTIVES: I. Overall survival (OS). II. Disease-specific survival (DSS). III. Toxicity (grade 3+, exclusive of expected alopecia). IV. Neurocognitive function (NCF). V. Outcomes and patient reported outcomes (PRO) measurements. VI. Adherence to protocol-specific target and normal tissue parameters. VII. Concordance measurements of central versus parent-institution pathology. VIII. Tissue microarray construction, and assessment of pHH3 mitotic index and molecular correlates to OS. OUTLINE: Patients are randomized to 1 of 2 arms after undergoing gross total resection. ARM I: Patients undergo observation. ARM II: Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions (59.4 Gy in 33 daily fractions of 1.8 Gy each). After completion of study treatment, patients are followed up at 3, 6, and 12 months, every 6 months for year 2 and 3, then yearly for 10 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03180268
Study type Interventional
Source NRG Oncology
Contact C. Leland Rogers, MD
Phone 602-406-6761
Email leland.rogers@dignityhealth.org
Status Recruiting
Phase Phase 3
Start date June 14, 2017
Completion date August 31, 2027

See also
  Status Clinical Trial Phase
Terminated NCT00972335 - Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma Phase 2
Recruiting NCT02523014 - Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas Phase 2
Active, not recruiting NCT02974127 - Multisession Radiosurgery in Large Meningiomas
Not yet recruiting NCT05832099 - Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints
Not yet recruiting NCT02084927 - Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery Phase 1